Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hongjin Xiaojie Capsule (HJXJC) is a multi-herb traditional Chinese medicine (TCM) formulation developed by Yunnan Yousheng Pharmaceutical. It is primarily indicated for the treatment of hyperplasia of mammary glands (breast hyperplasia) and associated breast pain (mastalgia), including moderate to severe cyclical breast pain. The formulation consists of several botanical ingredients, including *Mahonia*, *Bupleurum*, *Panax notoginseng*, golden buckwheat (*Fagopyrum dibotrys*), *Cyperus rotundus*, and *Paederia scandens*. According to TCM principles, the drug works by soothing the liver, regulating Qi, promoting blood circulation to remove stasis, and softening hardness to disperse nodules. Clinical evidence, including a Phase IV multicenter randomized controlled trial, supports its efficacy in reducing pain intensity and lump size in patients with breast hyperplasia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hongjin Xiaojie Capsule.